Department of Dermatology, The People's Hospital of Pingliang, Pingliang, China.
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8991-8999. doi: 10.26355/eurrev_201910_19299.
MicroRNAs are noncoding RNAs which are involved in the occurrence and progression of tumors. This study aims to explore the role of microRNA-92a in cutaneous malignant melanoma (CMM) and its underlying mechanism.
The expression level of microRNA-92a in 75 pairs of CMM tissues and paracancerous tissues was determined using quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlation between microRNA-92a expression with clinical data of CMM patients was analyzed. Besides, microRNA-92a expression in CMM cells and primary epidermal melanocytes (PEM) was determined by qRT-PCR as well. After transfection of si-microRNA-92a in CMM cells, biological performances of CMM were determined using cell counting kit-8 (CCK-8), colony formation and transwell assay, respectively. FOXP1 expression in CMM cells and tissues was determined using Western blot. Kaplan-Meier survival curves were drawn to explore the correlation between the FOXP1 expression and prognosis of CMM patients.
MicroRNA-92a was highly expressed in CMM tissues compared with that of paracancerous tissues. Compared with CMM patients with lower expression of microRNA-92a, those with higher expression of microRNA-92a presented higher tumor stage, higher incidences of lymph node metastasis and distant metastasis, as well as lower overall survival. The knockdown of microRNA-92a remarkably decreased proliferative, invasive and metastatic capacities of CMM cells. Western blot results elucidated that microRNA-92a knockdown in CMM cells upregulates FOXP1 expression. Additionally, rescue experiments showed that mi-croRNA-92a regulates biological performances of CMM cells by regulating FOXP1.
MicroRNA-92a is highly expressed in CMM, which is remarkably correlated to tumor stage and poor prognosis of CMM patients. We found that microRNA-92a pro-motes malignant progression of CMM by regulating FOXP1.
miRNA 是非编码 RNA，参与肿瘤的发生和发展。本研究旨在探讨 microRNA-92a 在皮肤恶性黑色素瘤（CMM）中的作用及其潜在机制。
采用实时定量聚合酶链反应（qRT-PCR）检测 75 对 CMM 组织和癌旁组织中 microRNA-92a 的表达水平。分析 microRNA-92a 表达与 CMM 患者临床资料的相关性。同时，采用 qRT-PCR 检测 CMM 细胞和原代表皮黑素细胞（PEM）中 microRNA-92a 的表达。用 si-microRNA-92a 转染 CMM 细胞后，分别用细胞计数试剂盒-8（CCK-8）、集落形成和 Transwell 实验测定 CMM 的生物学特性。采用 Western blot 检测 CMM 细胞和组织中 FOXP1 的表达。绘制 Kaplan-Meier 生存曲线，探讨 FOXP1 表达与 CMM 患者预后的相关性。
与癌旁组织相比，CMM 组织中 microRNA-92a 表达较高。与 microRNA-92a 低表达的 CMM 患者相比，microRNA-92a 高表达的 CMM 患者肿瘤分期较高，淋巴结转移和远处转移发生率较高，总生存率较低。microRNA-92a 敲低显著降低了 CMM 细胞的增殖、侵袭和转移能力。Western blot 结果表明，CMM 细胞中 microRNA-92a 敲低可上调 FOXP1 表达。此外，挽救实验表明，microRNA-92a 通过调节 FOXP1 调节 CMM 细胞的生物学特性。
microRNA-92a 在 CMM 中高表达，与 CMM 患者的肿瘤分期和预后显著相关。我们发现，microRNA-92a 通过调节 FOXP1 促进 CMM 的恶性进展。
